Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Venetoclax is a BCL-2 inhibitor that selectively binds to BCL-2 protein and inhibits anti-apoptotic function. This inhibition disrupts the interaction between BCL-2 and apoptosis r···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：271
Pemigatinib is a potent and selective oral antineoplastic drug targeting the FGFR subtype, primarily for the treatment of patients with advanced cholangiocarcinoma.How much is a bo···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：222
Pemigatinib is a targeted drug for cholangiocarcinoma, which has been marketed in many countries and regions around the world, and has achieved significant therapeutic effects and ···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：176
Venetoclax is a drug used to treat chronic lymphocytic leukemia (CLL) and certain types of acute myeloid leukemia (AML). It induces apoptosis in cancer cells by inhibiting the BCL-···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：288
Capmatinib is a targeted drug manufactured by Novartis for the treatment of patients with non-small cell lung cancer (NSCLC) with mutations in the MET gene. It stops the growth and···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：315
Capmatinib, trade name Tabrecta. It is an oral MET inhibitor mainly used for the treatment of non-small cell lung cancer with MET exon 14 skipping mutations. The drug can effective···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：295
Capmatinib is an oral, selective, ATP-competitive c-Met kinase inhibitor that inhibits c-Met kinase for the treatment of metastatic non-small cell lung cancer with mutations in MET···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：323
Pemigatinib is a targeted drug that is mainly used to treat cholangiocarcinoma.How many versions of Pemigatinib are there?From the perspective of drug specifications, Pemigatinib i···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：247
Capmatinib is a lung cancer drug that targets specific genetic mutations, especially for patients with non-small cell lung cancer with METex14 skipping mutations. The drug helps to···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：304
Pemigatinibis a targeted drug for the treatment of cholangiocarcinoma and belongs to the FGFR (fibroblast growth factor receptor) inhibitor class.What is Pemigatinib?Pemigatinibis ···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：251
Capmatinib is a targeted therapy for the treatment of non-small cell lung cancer harboring mutations in MET exon 14. It helps patients control the spread of pathological cells by i···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：299
Exkivity reduces the growth of non-small cell lung cancer by binding to and inhibiting EGFR exon 20 insertion mutations.What interactions can occur with other medicationsExkivity m···【more】
Article source：Captain MedicineRelease date：2024-08-09Recommended：268
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1592025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3992024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1552025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1732025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1532025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1882025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1682025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1642025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
